tetano
Editor, Senior Moderator
ACS Infect Dis
. 2022 Oct 31.
doi: 10.1021/acsinfecdis.2c00297. Online ahead of print.
High-Throughput Assay for Identifying Diverse Antagonists of the Binding Interaction between the ACE2 Receptor and the Dynamic Spike Proteins of SARS-CoV-2
Rachel M Sammons[SUP] 1 [/SUP], Amanda L Bohanon[SUP] 2 [/SUP], Anvith Kowtha[SUP] 3 [/SUP], Audrey Dejong[SUP] 3 [/SUP], Eun Jeong Cho[SUP] 1 [/SUP], Tamer S Kaoud[SUP] 1 3 [/SUP], Kevin N Dalby[SUP] 1 3 [/SUP]
Affiliations
Abstract
SARS-CoV-2, a coronavirus strain that started a worldwide pandemic in early 2020, attaches to human cells by binding its spike (S) glycoprotein to a host receptor protein angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the S protein and ACE2 has emerged as an important strategy for preventing viral infection. We systematically developed and optimized an AlphaLISA assay to investigate binding events between ACE2 and the ectodomain of the SARS-CoV-2 S protein (S-614G: residues 1-1208 with a D614G mutation). Using S-614G permits discovering potential allosteric inhibitors that stabilize the S protein in a conformation that impedes its access to ACE2. Over 30,000 small molecules were screened in a high-throughput format for activity against S-614G and ACE2 binding using the AlphaLISA assay. A viral entry assay was used to validate hits using lentiviral particles pseudotyped with the full-length S protein of the Wuhan-1 strain. Two compounds identified in the screen, oleic acid and suramin, blocked the attachment of S-614G to ACE2 and S protein-driven cell entry into Calu-3 and ACE2-overexpressing HEK293T cells. Oleic acid inhibits S-614G binding to ACE2 far more potently than to the receptor-binding domain (RBD, residues 319-541 of SARS-CoV-2 S), potentially indicating a noncompetitive mechanism. The results indicate that using the full-length ectodomain of the S protein can be important for identifying allosteric inhibitors of ACE2 binding. The approach reported here represents a rapidly adaptable format for discovering receptor-binding inhibitors to S-proteins of future coronavirus strains.
Keywords: COVID-19; SARS-CoV-2; high-throughput; inhibitor; spike protein; trimer.
. 2022 Oct 31.
doi: 10.1021/acsinfecdis.2c00297. Online ahead of print.
High-Throughput Assay for Identifying Diverse Antagonists of the Binding Interaction between the ACE2 Receptor and the Dynamic Spike Proteins of SARS-CoV-2
Rachel M Sammons[SUP] 1 [/SUP], Amanda L Bohanon[SUP] 2 [/SUP], Anvith Kowtha[SUP] 3 [/SUP], Audrey Dejong[SUP] 3 [/SUP], Eun Jeong Cho[SUP] 1 [/SUP], Tamer S Kaoud[SUP] 1 3 [/SUP], Kevin N Dalby[SUP] 1 3 [/SUP]
Affiliations
- PMID: 36315931
- DOI: 10.1021/acsinfecdis.2c00297
Abstract
SARS-CoV-2, a coronavirus strain that started a worldwide pandemic in early 2020, attaches to human cells by binding its spike (S) glycoprotein to a host receptor protein angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the S protein and ACE2 has emerged as an important strategy for preventing viral infection. We systematically developed and optimized an AlphaLISA assay to investigate binding events between ACE2 and the ectodomain of the SARS-CoV-2 S protein (S-614G: residues 1-1208 with a D614G mutation). Using S-614G permits discovering potential allosteric inhibitors that stabilize the S protein in a conformation that impedes its access to ACE2. Over 30,000 small molecules were screened in a high-throughput format for activity against S-614G and ACE2 binding using the AlphaLISA assay. A viral entry assay was used to validate hits using lentiviral particles pseudotyped with the full-length S protein of the Wuhan-1 strain. Two compounds identified in the screen, oleic acid and suramin, blocked the attachment of S-614G to ACE2 and S protein-driven cell entry into Calu-3 and ACE2-overexpressing HEK293T cells. Oleic acid inhibits S-614G binding to ACE2 far more potently than to the receptor-binding domain (RBD, residues 319-541 of SARS-CoV-2 S), potentially indicating a noncompetitive mechanism. The results indicate that using the full-length ectodomain of the S protein can be important for identifying allosteric inhibitors of ACE2 binding. The approach reported here represents a rapidly adaptable format for discovering receptor-binding inhibitors to S-proteins of future coronavirus strains.
Keywords: COVID-19; SARS-CoV-2; high-throughput; inhibitor; spike protein; trimer.